- Design
- randomised, parallel, open-label trial at a single centre
- Population
- 107 adults with end-stage kidney disease randomised before living or deceased donor kidney transplantation; 53 per arm transplanted
- Primary outcome
- 30-day rates of major surgical and vascular complications
- Effect
- major surgical complications 25% open against 13% robotic (risk difference -11%, 95% CI -26 to 3.4, P=0.2); vascular complications 19% against 9.4% (-9.4%, -23 to 3.7, P=0.3)
ORAKTx is the first randomised comparison of robot-assisted and open kidney transplantation. At a single Danish centre, 107 adults with end-stage kidney disease and no contraindication to robotic surgery were randomised before living or deceased donor transplantation; 53 in each arm were transplanted and completed follow-up. The primary outcomes were 30-day rates of major surgical and vascular complications.
Major surgical complications occurred in 13 patients (25%) in the open arm and seven (13%) in the robotic arm - a risk difference of -11% with a confidence interval running from -26% to +3.4% (P=0.2). Vascular complications occurred in 10 (19%) against five (9.4%), risk difference -9.4% (-23 to 3.7, P=0.3). Neither reached significance.
This is the situation where a negative trial and a promising result are the same result. Halving major complications would matter a great deal if real, and 106 transplanted patients is simply too few to distinguish an 11 percentage point reduction from chance - the interval is compatible with a large benefit and with a small harm. The authors say so. What the trial does establish is feasibility and safety in trained hands at a high-volume centre, which is the necessary first step. For Indian transplant units, where living donor transplantation is the mainstay and robotic systems are concentrated in a few private centres, this is a reason to watch the multicentre trial that has to follow, not to change a programme.
- Do not read this as evidence that robotic kidney transplantation reduces complications - the trial did not show it
- Do read it as evidence the approach is feasible and safe enough to justify a larger trial
- Note the exclusion: patients with a contraindication to robotic surgery were not randomised, so this does not apply to every recipient
- Weigh the resource question honestly - robotic transplantation concentrates the operation in fewer centres
- Keep open transplantation as the standard until an adequately powered comparison reports
Why it matters
It is the first randomised evidence on a technique already being adopted, and it shows the question is still open.
Don't overread it
Single centre, open label, 106 transplanted patients - the apparent halving of complications is not a demonstrated benefit.
The statistics, in plain English
A risk difference of -11% with an interval from -26% to +3.4% is the definition of an inconclusive result: it is compatible with preventing one major complication in every four patients, and with causing a small increase. The observed halving of complications is exactly what a promising underpowered trial looks like, and also exactly what chance produces reasonably often when events are counted in single figures. A P value of 0.2 here should be read as 'not yet answered', not as 'no difference'.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free